SPY is an exchange-traded fund (ETF) that aims to replicate the performance of the S&P 500 Index. The S&P 500 Index includes 500 of the largest publicly traded companies in the United States, representing a broad cross-section of the U.S. economy.
Metrics and analysis →INCY
INCY stands for Incyte Corporation, a biopharmaceutical company focused on developing novel medicines.
- Open
- 113.68
- High
- 117.51
- Low
- 113.68
- Prev close
- 115.87
- Volume
- 2M
- Avg vol 10
- 1M
Today · Market closed · opens Mon 9:30 AM
INCY chart
Scroll or pinch to zoom, drag to pan, or use the buttons on the chart. About the price history
Technical analysis
Daily bars · last bar Nov 20, 2026 · close 113.91
Leaning sell. 5 of 18 signals point down against 3 up, carried by trend. Momentum is mostly neutral. Volatility is mostly neutral. Volume is mostly neutral. Stochastic, Stoch RSI, Williams %R and CCI sit in oversold territory. Trend strength is weak (ADX 11).
Trend
Momentum
Volatility
Volume
Strong sell. The close is above 4 of 24 averages and below 20. Short- and long-term averages agree: price is below both. SMA 50 is above SMA 200 (118.48 vs 109.31).
| Period | SMA | EMA | WMA | WEMA |
|---|---|---|---|---|
| 5 | 117.39 | 116.80 | 116.33 | 117.93 |
| 10 | 119.41 | 118.06 | 118.19 | 118.31 |
| 20 | 118.81 | 118.31 | 119.01 | 118.42 |
| 50 | 118.48 | 118.43 | 117.72 | 116.76 |
| 100 | 120.04 | 116.69 | 119.58 | 111.31 |
| 200 | 109.31 | 111.00 | 114.79 | 104.56 |
Green: the close is above that average. Red: below it.
From the bar before the last one. Nearest classic support is S2 at 113.67. Nearest resistance is S1 at 114.77.
| Level | Classic | Fibonacci | Camarilla | Floor | Woodie | DeMark |
|---|---|---|---|---|---|---|
| R3 | 122.46 | 119.53 | 116.68 | 120.63 | 121.25 | — |
| R2 | 119.53 | 118.41 | 116.41 | 119.53 | 119.84 | — |
| R1 | 117.70 | 117.72 | 116.14 | 117.70 | 118.32 | 117.15 |
| Pivot | 116.60 | 116.60 | 116.60 | 116.60 | 116.91 | 116.33 |
| S1 | 114.77 | 115.48 | 115.60 | 114.77 | 115.39 | 114.22 |
| S2 | 113.67 | 114.79 | 115.33 | 113.67 | 113.98 | — |
| S3 | 110.74 | 113.67 | 115.06 | 111.84 | 112.45 | — |
Patterns that formed on the last 5 bars, newest first.
A candle with a long body and short shadows.
Sellers controlled the bar.
A candle with a short body and short shadows: a quiet bar.
A small loss on little range; weak on its own.
A small body at the bottom of the candle with a long upper shadow, after a decline.
Buyers tested higher prices; a turn up may follow, best confirmed by the next candle.
A small body with shadows longer than the body on both sides.
Neither side won the bar. On its own it says little; after a strong move it warns the move is tiring.
How candlestick references usually rate the pattern. It is not a success rate measured on this ticker. About candle patterns
| Date | Open | High | Low | Close | Volume | Change |
|---|---|---|---|---|---|---|
| Nov 20, 2026 | 116.85 | 117.51 | 113.91 | 113.91 | 2M | −2.94 |
| Nov 19, 2026 | 117.80 | 118.43 | 115.50 | 115.87 | 1M | −1.93 |
| Nov 18, 2026 | 118.77 | 120.99 | 117.76 | 117.80 | 1M | −0.97 |
| Nov 17, 2026 | 119.95 | 121.43 | 118.05 | 119.09 | 2M | −0.86 |
| Nov 16, 2026 | 121.98 | 122.94 | 119.79 | 120.27 | 2M | −1.71 |
| Nov 13, 2026 | 121.89 | 122.07 | 119.72 | 120.97 | 951K | −0.92 |
| Nov 12, 2026 | 123.09 | 123.90 | 121.29 | 121.70 | 1M | −1.39 |
| Nov 11, 2026 | 119.37 | 122.73 | 117.84 | 122.27 | 1M | +2.90 |
| Nov 10, 2026 | 120.58 | 121.25 | 119.03 | 120.30 | 2M | −0.28 |
| Nov 9, 2026 | 120.59 | 122.07 | 118.26 | 121.89 | 1M | +1.30 |
| Nov 6, 2026 | 116.38 | 119.81 | 115.00 | 119.65 | 1M | +3.27 |
| Nov 5, 2026 | 123.96 | 123.96 | 117.88 | 118.01 | 2M | −5.95 |
| Nov 4, 2026 | 117.52 | 123.33 | 117.52 | 122.85 | 2M | +5.33 |
| Nov 3, 2026 | 118.96 | 121.26 | 117.27 | 117.59 | 2M | −1.37 |
| Nov 2, 2026 | 119.02 | 121.52 | 118.25 | 120.04 | 2M | +1.02 |
| Oct 30, 2026 | 120.10 | 122.87 | 119.55 | 120.39 | 3M | +0.29 |
| Oct 29, 2026 | 111.64 | 117.09 | 111.01 | 116.80 | 3M | +5.16 |
| Oct 28, 2026 | 115.50 | 118.49 | 114.74 | 116.87 | 2M | +1.37 |
| Oct 27, 2026 | 111.18 | 116.76 | 111.18 | 116.60 | 2M | +5.42 |
| Oct 26, 2026 | 115.49 | 115.93 | 112.75 | 113.31 | 2M | −2.18 |
| Oct 23, 2026 | 116.75 | 116.87 | 115.12 | 115.71 | 1M | −1.04 |
| Oct 22, 2026 | 113.93 | 117.17 | 112.76 | 116.93 | 2M | +3.00 |
| Oct 21, 2026 | 115.98 | 116.57 | 113.35 | 113.44 | 1M | −2.54 |
| Oct 20, 2026 | 113.78 | 117.00 | 113.26 | 116.62 | 1M | +2.84 |
| Oct 19, 2026 | 113.19 | 114.38 | 112.71 | 113.25 | 1M | +0.06 |
| Oct 16, 2026 | 113.98 | 114.57 | 112.02 | 113.07 | 2M | −0.91 |
| Oct 15, 2026 | 112.71 | 116.03 | 112.60 | 113.27 | 2M | +0.56 |
| Oct 14, 2026 | 108.61 | 112.06 | 107.83 | 111.57 | 2M | +2.96 |
| Oct 13, 2026 | 111.29 | 111.68 | 107.78 | 108.62 | 3M | −2.67 |
| Oct 12, 2026 | 114.05 | 114.05 | 111.26 | 111.36 | 1M | −2.69 |
Performance
Daily returns for Jan 1, 2026 – Nov 22, 2026 (YTD). About the returns · About the risk figures
1 month return
-1.97%
Change in value over the past month.
3 month return
-10.43%
Change in value over the last three months.
Max drawdown
18.33%
Largest fall from a peak to the low that followed.
Standard deviation
32.94%
How far daily returns stray from their average, annualised.
Sharpe ratio
0.58
Return above the risk-free rate per unit of volatility.
Calmar ratio
1.04
Annualised return against the maximum drawdown.
INCY summary
Loading summary…
INCY, answered
What is Incyte’s approach to drug development?
Incyte employs a science-driven approach, focusing on molecularly targeted therapies to address unmet medical needs.
What is Incyte’s flagship product?
Incyte’s flagship product is Jakafi (ruxolitinib), used to treat certain types of blood cancer.
When was Incyte founded?
Incyte was founded in 1991 and has been dedicated to oncology and other serious diseases.
How can investors learn more about Incyte?
Investors can visit Incyte’s official website for detailed information on financial performance and corporate updates.
What are Incyte’s primary areas of focus?
Incyte primarily focuses on oncology, hematology, and other unmet medical needs.
What partnerships does Incyte have?
Incyte partners with other pharmaceutical companies and academic institutions to enhance its research capabilities.
How does Incyte contribute to patient communities?
Incyte engages with patient communities to provide support and educational resources about their conditions and treatments.
How does Jakafi work?
Jakafi works by inhibiting specific enzymes involved in cell signaling pathways that contribute to cancer.
What other therapies does Incyte offer?
Incyte offers additional therapies for various conditions, including ruxolitinib for myelofibrosis and graft-versus-host disease.
Does Incyte conduct clinical trials?
Yes, Incyte conducts numerous clinical trials to evaluate the safety and efficacy of its drug candidates.
INCY in the news
Top market assets
Discover our curated selection of top-performing exchange-traded funds (ETFs) that represent a diverse range of investment opportunities.
QQQ is an exchange-traded fund (ETF) that tracks the performance of the Nasdaq-100 Index. This index includes 100 of the largest non-financial companies listed on the Nasdaq Stock Market, primarily focusing on technology and innovation sectors.
Metrics and analysis →DIA is an exchange-traded fund (ETF) that aims to track the performance of the Dow Jones Industrial Average (DJIA). The DJIA is a stock market index consisting of 30 large, publicly traded companies in the United States, representing a broad range of industries.
Metrics and analysis →IWM is an exchange-traded fund (ETF) that seeks to track the performance of the Russell 2000 Index. The Russell 2000 Index measures the performance of the 2,000 smallest stocks in the Russell 3000 Index, representing a broad segment of small-cap U.S. companies.
Metrics and analysis →Optimize Your INCY Trading Now
Elevate your trading strategy with OHLCX execution platform’s sophisticated tools for INCY. Our system integrates cutting-edge technology and expert analysis to support your investment goals. Start optimizing your trades today and explore the benefits of advanced trading now!
Disclaimers
The information displayed on this site is sourced from third-party providers and is believed to be reliable. OHLCX has not independently verified this data and does not guarantee its accuracy. Content is for educational and informational purposes only and is not financial or investment advice.
With any investment, your capital is at risk. Past performance is no guarantee of future results. Consult your provider's terms and privacy policies where applicable.
Prices, charts and every figure derived from them are delayed by at least 15 minutes and are provided for information only; we do not guarantee their accuracy or timeliness.
Securities products are: Not FDIC insured · Not bank guaranteed · May lose value
Trademarks and logos are the property of their respective owners and do not represent endorsements of any kind.